Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
19 Outubro 2022 - 8:00AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced that three abstracts
have been selected for presentation as posters at the
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics, being held in Barcelona, Spain from October 26-28,
2022.
Details on the Tango presentations at the EORTC-NCI-AACR
Symposium are as follows:
Poster Title: Biochemical characterization
of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for
the treatment of MTAP-deleted cancersAbstract
#: 75Date and Time: Wednesday,
October 26, 12:00 PM CEST
Poster Title: TNG908 is a brain-penetrant,
MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted
cancerAbstract #: 233Date and
Time: Thursday, October 27, 10:00 AM CEST
Poster Title: TNG462 is a potential
best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of
peripheral MTAP-deleted solid tumorsAbstract
#: 234Date and Time: Thursday,
October 27, 10:00 AM CEST
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered
forward-looking statements. Forward-looking statements generally
relate to future events, Tango’s future operating performance and
goals, the anticipated benefits of therapies and combination
therapies (that include a Tango pipeline product), expectations,
beliefs and development objectives for Tango’s product pipeline and
clinical trials. In some cases, you can identify forward-looking
statements by terminology such as “may”, “should”, “expect”,
“intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. For example,
statements concerning the following include or constitute
forward-looking statements: the expected benefits of TNG908 and the
Company's other development candidates and other product candidates
(as a standalone therapy of in combination with other therapies);
TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor
for the treatment of peripheral MTAP-deleted solid tumors; and the
expected timing of: (i) development candidate declaration for
certain targets; (ii) initiating IND-enabling studies; (iii) filing
INDs; (iv) clinical trial initiation; and (v) disclosing initial
and final clinical trial results. Such forward-looking statements
are subject to risks, uncertainties, and other factors which could
cause actual results to differ materially from those expressed or
implied by such forward looking statements. These forward-looking
statements are based upon estimates and assumptions that, while
considered reasonable by Tango and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: Tango has limited experience conducting clinical trials (and
will rely on a third party to operate the clinical trial for
TNG908) and may not be able to commence the clinical trial
(including opening clinical trial sites and enrolling and dosing an
adequate number of clinical trial participants) when expected and
may not generate results (including final or initial safety and
efficacy data) in the anticipated timeframe (or at all); benefits
of product candidates seen in preclinical analyses may not be
evident when tested in clinical trials or when used in broader
patient populations (if approved for commercial sale); the benefits
of Tango pipeline products, development candidates and potential
combination therapies that are seen in pre-clinical experiments may
not be present in clinical trials or in use commercially or may not
be safe and/or effective in humans; Tango has a limited operating
history and has not generated any revenue to date from drug sales,
and may never become profitable; the Company may not be able to
file INDs for development candidates on time, or at all, due to
technical or financial reasons or otherwise; Tango will need to
raise capital in the future and if we are unable to raise capital
when needed or on attractive terms, we would be forced to delay,
scale back or discontinue some of our development programs or
future commercialization efforts; we may be unable to advance our
preclinical development programs into and through the clinic for
safety or efficacy reasons or commercialize our product candidates
or we may experience significant delays in doing so as a result of
factors beyond Tango’s control; Tango’s approach to the discovery
and development of product candidates is novel and unproven, which
makes it difficult to predict the time, cost of development, and
likelihood of successfully developing any products; our products
candidates may cause adverse or other undesirable side effects (or
may not show requisite efficacy) that could, among other things,
delay or prevent regulatory approval; our ability to obtain and
maintain patent and other intellectual property protection for our
technology and product candidates or the scope of intellectual
property protection obtained is not sufficiently broad; and delays
and other impacts on product development and clinical trials from
the COVID-19 pandemic. Additional information concerning risks,
uncertainties and assumptions can be found in Tango’s filings with
the SEC, including the risk factors referenced in Tango’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021, as
supplemented and/or modified by its most recent Quarterly Report on
Form 10-Q. You should not place undue reliance on forward-looking
statements in this press release, which speak only as of the date
they are made and are qualified in their entirety by reference to
the cautionary statements herein. Tango specifically disclaims any
duty to update these forward-looking statements.
Investor Contact:
Sam Martin/Andrew VulisArgot Partnerstango@argotpartners.com
Media Contact:
Joshua R. Mansbach Argot Partners tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024